 Myron Levin
Concepts (849)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpes Zoster | 105 | 2024 | 314 | 18.200 |
Why?
| | Herpes Zoster Vaccine | 65 | 2024 | 155 | 16.680 |
Why?
| | Herpesvirus 3, Human | 86 | 2024 | 331 | 12.300 |
Why?
| | Chickenpox | 24 | 2023 | 81 | 5.080 |
Why?
| | Antibodies, Viral | 66 | 2024 | 649 | 4.990 |
Why?
| | Immunity, Cellular | 36 | 2024 | 270 | 4.610 |
Why?
| | Chickenpox Vaccine | 27 | 2023 | 74 | 3.850 |
Why?
| | Influenza Vaccines | 18 | 2024 | 529 | 2.890 |
Why?
| | Vaccines, Attenuated | 32 | 2024 | 130 | 2.710 |
Why?
| | HIV Infections | 38 | 2018 | 2943 | 2.470 |
Why?
| | Neuralgia, Postherpetic | 18 | 2019 | 40 | 2.420 |
Why?
| | Immunocompromised Host | 13 | 2019 | 205 | 2.380 |
Why?
| | Antiviral Agents | 28 | 2022 | 761 | 2.270 |
Why?
| | Adjuvants, Immunologic | 17 | 2023 | 238 | 2.110 |
Why?
| | Simplexvirus | 24 | 2016 | 82 | 2.100 |
Why?
| | Acyclovir | 27 | 2016 | 95 | 2.040 |
Why?
| | Herpes Simplex | 17 | 2016 | 95 | 1.890 |
Why?
| | Vaccination | 33 | 2023 | 1432 | 1.800 |
Why?
| | DNA, Viral | 24 | 2018 | 368 | 1.730 |
Why?
| | Trypanosoma cruzi | 13 | 2007 | 40 | 1.680 |
Why?
| | Papillomavirus Vaccines | 13 | 2018 | 316 | 1.490 |
Why?
| | Viral Envelope Proteins | 6 | 2021 | 97 | 1.460 |
Why?
| | Herpesvirus 1, Human | 10 | 2016 | 81 | 1.450 |
Why?
| | Pregnancy Complications, Infectious | 16 | 2020 | 397 | 1.410 |
Why?
| | Influenza, Human | 13 | 2024 | 608 | 1.390 |
Why?
| | Humans | 293 | 2024 | 138201 | 1.360 |
Why?
| | T-Lymphocytes | 20 | 2019 | 1982 | 1.360 |
Why?
| | Vaccines, Synthetic | 15 | 2023 | 127 | 1.340 |
Why?
| | Antiretroviral Therapy, Highly Active | 13 | 2017 | 280 | 1.320 |
Why?
| | Aged | 92 | 2024 | 24134 | 1.320 |
Why?
| | Aged, 80 and over | 47 | 2022 | 7683 | 1.290 |
Why?
| | Immunologic Memory | 12 | 2019 | 358 | 1.280 |
Why?
| | Immunization, Secondary | 13 | 2017 | 87 | 1.250 |
Why?
| | CD4-Positive T-Lymphocytes | 13 | 2023 | 1101 | 1.220 |
Why?
| | Antibodies, Protozoan | 5 | 2007 | 36 | 1.150 |
Why?
| | Papillomavirus Infections | 9 | 2018 | 378 | 1.110 |
Why?
| | Middle Aged | 101 | 2024 | 33711 | 1.100 |
Why?
| | Ribosomal Proteins | 6 | 2006 | 92 | 1.060 |
Why?
| | Chagas Disease | 8 | 2007 | 44 | 1.030 |
Why?
| | Female | 155 | 2023 | 73713 | 1.010 |
Why?
| | Protozoan Proteins | 6 | 2006 | 83 | 1.010 |
Why?
| | Double-Blind Method | 32 | 2022 | 1936 | 1.000 |
Why?
| | Male | 138 | 2023 | 68035 | 0.970 |
Why?
| | T-Lymphocyte Subsets | 6 | 2019 | 417 | 0.950 |
Why?
| | Vaccines, Inactivated | 9 | 2023 | 67 | 0.900 |
Why?
| | Receptors, Adrenergic, beta-1 | 4 | 2007 | 23 | 0.890 |
Why?
| | Viral Vaccines | 12 | 2014 | 107 | 0.880 |
Why?
| | Incidence | 22 | 2023 | 2820 | 0.860 |
Why?
| | Herpesvirus 2, Human | 6 | 2014 | 29 | 0.850 |
Why?
| | Virus Latency | 4 | 2014 | 79 | 0.820 |
Why?
| | Interferon-gamma | 18 | 2022 | 788 | 0.820 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2019 | 73 | 0.810 |
Why?
| | Immune Sera | 4 | 2020 | 84 | 0.800 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2018 | 912 | 0.790 |
Why?
| | Pneumococcal Vaccines | 3 | 2021 | 135 | 0.780 |
Why?
| | B-Lymphocytes | 9 | 2021 | 856 | 0.780 |
Why?
| | Injections, Intramuscular | 5 | 2022 | 130 | 0.780 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 22 | 2021 | 851 | 0.770 |
Why?
| | Influenza A Virus, H1N1 Subtype | 6 | 2017 | 147 | 0.740 |
Why?
| | Respiratory Syncytial Virus Vaccines | 2 | 2019 | 35 | 0.730 |
Why?
| | Age Factors | 17 | 2021 | 3262 | 0.730 |
Why?
| | Antibodies, Neutralizing | 12 | 2023 | 302 | 0.720 |
Why?
| | Drug Resistance, Viral | 7 | 2009 | 118 | 0.720 |
Why?
| | Rotavirus Infections | 3 | 2017 | 39 | 0.710 |
Why?
| | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 6 | 2017 | 15 | 0.710 |
Why?
| | Influenza B virus | 6 | 2012 | 44 | 0.680 |
Why?
| | Anti-Retroviral Agents | 5 | 2018 | 246 | 0.670 |
Why?
| | Vaccination Coverage | 2 | 2018 | 89 | 0.660 |
Why?
| | Rotavirus Vaccines | 2 | 2017 | 42 | 0.640 |
Why?
| | Adenovirus Infections, Human | 4 | 2015 | 15 | 0.630 |
Why?
| | Infectious Disease Transmission, Vertical | 7 | 2020 | 185 | 0.630 |
Why?
| | Down Syndrome | 2 | 2023 | 486 | 0.630 |
Why?
| | Adult | 76 | 2024 | 38190 | 0.620 |
Why?
| | Clinical Trials as Topic | 15 | 2019 | 1032 | 0.610 |
Why?
| | Polymerase Chain Reaction | 13 | 2019 | 1049 | 0.600 |
Why?
| | Th1 Cells | 3 | 2018 | 142 | 0.600 |
Why?
| | Insurance Claim Review | 1 | 2019 | 84 | 0.580 |
Why?
| | HIV | 4 | 2010 | 246 | 0.580 |
Why?
| | Child, Preschool | 42 | 2024 | 11115 | 0.580 |
Why?
| | AIDS-Related Opportunistic Infections | 4 | 2015 | 128 | 0.580 |
Why?
| | Cytomegalovirus Infections | 4 | 2015 | 192 | 0.580 |
Why?
| | Influenza A Virus, H3N2 Subtype | 4 | 2017 | 46 | 0.580 |
Why?
| | Alphapapillomavirus | 4 | 2016 | 39 | 0.570 |
Why?
| | CD4 Lymphocyte Count | 14 | 2017 | 279 | 0.570 |
Why?
| | Antibody Formation | 8 | 2023 | 299 | 0.560 |
Why?
| | Infant | 31 | 2023 | 9553 | 0.550 |
Why?
| | Immunoglobulin G | 11 | 2021 | 903 | 0.550 |
Why?
| | Dose-Response Relationship, Immunologic | 3 | 2016 | 85 | 0.550 |
Why?
| | Virus Shedding | 6 | 2017 | 46 | 0.550 |
Why?
| | Child | 59 | 2024 | 21862 | 0.540 |
Why?
| | Pneumonia | 1 | 2023 | 640 | 0.530 |
Why?
| | Health Expenditures | 1 | 2019 | 193 | 0.530 |
Why?
| | Anti-HIV Agents | 6 | 2015 | 836 | 0.530 |
Why?
| | Pain | 6 | 2022 | 764 | 0.520 |
Why?
| | Herpesviridae Infections | 4 | 2015 | 148 | 0.520 |
Why?
| | Cytosine | 3 | 2015 | 48 | 0.520 |
Why?
| | Adolescent | 53 | 2024 | 21503 | 0.520 |
Why?
| | Interleukin-2 | 7 | 2022 | 451 | 0.510 |
Why?
| | Infant, Premature | 5 | 2020 | 580 | 0.510 |
Why?
| | Antigens, Viral | 21 | 2017 | 179 | 0.500 |
Why?
| | Organophosphonates | 2 | 2015 | 99 | 0.490 |
Why?
| | Cytomegalovirus | 7 | 2006 | 159 | 0.490 |
Why?
| | Injections, Subcutaneous | 1 | 2016 | 162 | 0.480 |
Why?
| | Follow-Up Studies | 22 | 2019 | 5160 | 0.470 |
Why?
| | Enzyme-Linked Immunospot Assay | 4 | 2018 | 37 | 0.470 |
Why?
| | Guanine | 14 | 2006 | 81 | 0.470 |
Why?
| | Refrigeration | 2 | 2018 | 12 | 0.460 |
Why?
| | Health Care Costs | 1 | 2018 | 418 | 0.450 |
Why?
| | Polyomavirus Infections | 1 | 2015 | 31 | 0.450 |
Why?
| | Immunity, Humoral | 3 | 2021 | 117 | 0.450 |
Why?
| | Viral Load | 12 | 2018 | 499 | 0.450 |
Why?
| | Immunization | 5 | 2014 | 405 | 0.450 |
Why?
| | Skin Diseases | 1 | 2016 | 146 | 0.440 |
Why?
| | Oropharynx | 1 | 2014 | 45 | 0.440 |
Why?
| | Uterine Cervical Neoplasms | 5 | 2016 | 290 | 0.440 |
Why?
| | Herpes Genitalis | 7 | 2014 | 18 | 0.440 |
Why?
| | Blood | 1 | 2014 | 110 | 0.430 |
Why?
| | Infant, Newborn | 28 | 2023 | 6133 | 0.420 |
Why?
| | Immunogenicity, Vaccine | 4 | 2022 | 34 | 0.410 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2016 | 388 | 0.400 |
Why?
| | Vaccines | 3 | 2018 | 402 | 0.400 |
Why?
| | Herpes Labialis | 3 | 2013 | 8 | 0.390 |
Why?
| | Time Factors | 20 | 2021 | 6848 | 0.390 |
Why?
| | Trigeminal Ganglion | 2 | 2003 | 23 | 0.390 |
Why?
| | Placebos | 8 | 2017 | 197 | 0.390 |
Why?
| | Aging | 10 | 2017 | 1852 | 0.380 |
Why?
| | Post-Exposure Prophylaxis | 2 | 2023 | 12 | 0.370 |
Why?
| | Retrospective Studies | 16 | 2023 | 15842 | 0.370 |
Why?
| | Sensory Receptor Cells | 1 | 2012 | 96 | 0.370 |
Why?
| | Young Adult | 24 | 2023 | 13298 | 0.370 |
Why?
| | RNA, Viral | 21 | 2018 | 688 | 0.360 |
Why?
| | Communicable Diseases | 1 | 2014 | 161 | 0.360 |
Why?
| | United States | 17 | 2023 | 14983 | 0.350 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2021 | 1479 | 0.350 |
Why?
| | Quality of Life | 7 | 2021 | 2952 | 0.340 |
Why?
| | Human papillomavirus 18 | 5 | 2018 | 16 | 0.330 |
Why?
| | Pregnancy | 20 | 2020 | 6792 | 0.320 |
Why?
| | Human papillomavirus 16 | 5 | 2018 | 33 | 0.320 |
Why?
| | Databases, Factual | 4 | 2019 | 1391 | 0.320 |
Why?
| | Animals | 42 | 2021 | 37129 | 0.320 |
Why?
| | Glycoproteins | 2 | 2023 | 359 | 0.320 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2012 | 248 | 0.320 |
Why?
| | Chagas Cardiomyopathy | 4 | 2007 | 23 | 0.310 |
Why?
| | Cost-Benefit Analysis | 4 | 2024 | 605 | 0.310 |
Why?
| | Poverty | 1 | 2013 | 522 | 0.310 |
Why?
| | Vaccines, Subunit | 5 | 2021 | 50 | 0.300 |
Why?
| | Risk Factors | 20 | 2023 | 10366 | 0.300 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2009 | 19 | 0.300 |
Why?
| | Frail Elderly | 2 | 2020 | 130 | 0.300 |
Why?
| | Treatment Outcome | 19 | 2016 | 10914 | 0.290 |
Why?
| | Varicella Zoster Virus Infection | 2 | 2018 | 24 | 0.280 |
Why?
| | Epitopes | 4 | 2005 | 476 | 0.280 |
Why?
| | Activities of Daily Living | 3 | 2021 | 419 | 0.270 |
Why?
| | Meningitis, Viral | 3 | 1997 | 20 | 0.270 |
Why?
| | Meningitis | 1 | 2008 | 81 | 0.270 |
Why?
| | Hemagglutination Inhibition Tests | 7 | 2017 | 38 | 0.270 |
Why?
| | Seasons | 3 | 2023 | 538 | 0.270 |
Why?
| | Autoantibodies | 3 | 2007 | 1454 | 0.260 |
Why?
| | Viral Plaque Assay | 8 | 2012 | 33 | 0.260 |
Why?
| | Research Design | 2 | 2013 | 1117 | 0.260 |
Why?
| | Recurrence | 14 | 2019 | 1102 | 0.260 |
Why?
| | Cells, Cultured | 19 | 2012 | 4159 | 0.260 |
Why?
| | Cytokines | 7 | 2018 | 2080 | 0.260 |
Why?
| | Viremia | 5 | 2018 | 152 | 0.260 |
Why?
| | Prospective Studies | 25 | 2019 | 7611 | 0.250 |
Why?
| | Neurons | 6 | 2003 | 1594 | 0.250 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2017 | 125 | 0.240 |
Why?
| | Immunocompetence | 4 | 2019 | 43 | 0.240 |
Why?
| | Neoplasms | 3 | 2016 | 2694 | 0.240 |
Why?
| | Nucleic Acid Hybridization | 11 | 2006 | 188 | 0.240 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 4 | 2017 | 253 | 0.230 |
Why?
| | Sleep Wake Disorders | 4 | 2013 | 300 | 0.230 |
Why?
| | Virus Replication | 12 | 2018 | 528 | 0.230 |
Why?
| | Nucleosides | 1 | 2004 | 26 | 0.220 |
Why?
| | Cross Reactions | 6 | 2014 | 130 | 0.220 |
Why?
| | Severity of Illness Index | 14 | 2015 | 2857 | 0.220 |
Why?
| | Cell Count | 2 | 2005 | 320 | 0.220 |
Why?
| | Intestines | 2 | 2018 | 356 | 0.220 |
Why?
| | Vaccine Potency | 3 | 2019 | 6 | 0.220 |
Why?
| | Viral Proteins | 5 | 2018 | 361 | 0.220 |
Why?
| | Influenza A virus | 5 | 2012 | 110 | 0.220 |
Why?
| | Molecular Sequence Data | 9 | 2006 | 2925 | 0.220 |
Why?
| | Nonlinear Dynamics | 1 | 2005 | 88 | 0.220 |
Why?
| | Health Resources | 2 | 2019 | 125 | 0.220 |
Why?
| | Depressive Disorder, Major | 4 | 2013 | 374 | 0.210 |
Why?
| | Phosphoproteins | 1 | 2006 | 340 | 0.210 |
Why?
| | Interferons | 9 | 1982 | 202 | 0.210 |
Why?
| | Herpesvirus 4, Human | 3 | 2014 | 165 | 0.210 |
Why?
| | Monocytes | 7 | 2005 | 572 | 0.210 |
Why?
| | Cholecalciferol | 1 | 2024 | 60 | 0.210 |
Why?
| | Neuralgia | 4 | 2010 | 134 | 0.210 |
Why?
| | Genetic Variation | 1 | 2008 | 1002 | 0.200 |
Why?
| | Immunoassay | 2 | 2017 | 113 | 0.200 |
Why?
| | Long-Term Care | 1 | 2024 | 106 | 0.200 |
Why?
| | Antibody Affinity | 2 | 2021 | 60 | 0.200 |
Why?
| | Cricetinae | 6 | 2007 | 296 | 0.200 |
Why?
| | Enterovirus Infections | 5 | 1995 | 173 | 0.200 |
Why?
| | Encephalitis | 2 | 1995 | 136 | 0.200 |
Why?
| | Ganglia, Spinal | 2 | 1993 | 78 | 0.190 |
Why?
| | Developing Countries | 2 | 2016 | 312 | 0.190 |
Why?
| | Drug Combinations | 2 | 2022 | 343 | 0.190 |
Why?
| | CHO Cells | 3 | 2007 | 167 | 0.190 |
Why?
| | Pain Measurement | 8 | 2019 | 531 | 0.190 |
Why?
| | Lymphocyte Activation | 13 | 2015 | 1145 | 0.190 |
Why?
| | Virus Activation | 4 | 2010 | 85 | 0.190 |
Why?
| | Recombinant Proteins | 4 | 2018 | 1354 | 0.190 |
Why?
| | Lymphocytosis | 1 | 2021 | 11 | 0.180 |
Why?
| | Papillomaviridae | 3 | 2011 | 133 | 0.180 |
Why?
| | Longitudinal Studies | 8 | 2018 | 2837 | 0.180 |
Why?
| | Mice | 12 | 2021 | 17761 | 0.180 |
Why?
| | Immunosenescence | 1 | 2021 | 5 | 0.180 |
Why?
| | Cell Separation | 1 | 2002 | 317 | 0.170 |
Why?
| | Fetal Diseases | 4 | 1991 | 173 | 0.170 |
Why?
| | Herpes Simplex Virus Vaccines | 2 | 2012 | 4 | 0.170 |
Why?
| | Genes, Protozoan | 1 | 2000 | 13 | 0.170 |
Why?
| | Fibroblasts | 10 | 2018 | 1000 | 0.170 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 77 | 0.170 |
Why?
| | Virology | 1 | 2001 | 36 | 0.170 |
Why?
| | Fluorescent Antibody Technique | 6 | 2016 | 384 | 0.170 |
Why?
| | Intermediate Filament Proteins | 1 | 2000 | 58 | 0.170 |
Why?
| | Case-Control Studies | 5 | 2018 | 3574 | 0.170 |
Why?
| | RNA Helicases | 1 | 2000 | 30 | 0.170 |
Why?
| | Cell Line | 16 | 2018 | 2865 | 0.170 |
Why?
| | Amino Acid Sequence | 5 | 2006 | 2159 | 0.170 |
Why?
| | Vitamin D | 1 | 2024 | 399 | 0.170 |
Why?
| | Terminal Repeat Sequences | 1 | 2000 | 18 | 0.160 |
Why?
| | Immunoglobulin A | 3 | 2017 | 214 | 0.160 |
Why?
| | Feces | 3 | 2017 | 480 | 0.160 |
Why?
| | Short Interspersed Nucleotide Elements | 1 | 2000 | 11 | 0.160 |
Why?
| | Health Services for the Aged | 1 | 2001 | 77 | 0.160 |
Why?
| | HIV-1 | 5 | 2018 | 887 | 0.160 |
Why?
| | Enterovirus | 3 | 1995 | 85 | 0.160 |
Why?
| | Laboratories | 1 | 2001 | 108 | 0.160 |
Why?
| | Cohort Studies | 10 | 2022 | 5717 | 0.160 |
Why?
| | Antidepressive Agents | 2 | 2013 | 245 | 0.160 |
Why?
| | Carrier Proteins | 2 | 2001 | 737 | 0.160 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 1993 | 233 | 0.160 |
Why?
| | Retroelements | 1 | 2000 | 48 | 0.160 |
Why?
| | Myocytes, Cardiac | 1 | 2004 | 506 | 0.160 |
Why?
| | Epitope Mapping | 3 | 2005 | 61 | 0.160 |
Why?
| | Immunoenzyme Techniques | 3 | 2006 | 209 | 0.160 |
Why?
| | Immunization, Passive | 4 | 1994 | 92 | 0.160 |
Why?
| | Leukocytes, Mononuclear | 5 | 2010 | 569 | 0.160 |
Why?
| | Dietary Supplements | 1 | 2024 | 562 | 0.160 |
Why?
| | Base Sequence | 10 | 2007 | 2180 | 0.160 |
Why?
| | Pneumococcal Infections | 2 | 2013 | 109 | 0.150 |
Why?
| | Hemophilia A | 2 | 1993 | 141 | 0.150 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2022 | 281 | 0.150 |
Why?
| | Immunization Schedule | 3 | 2016 | 202 | 0.150 |
Why?
| | Myocardium | 3 | 2001 | 907 | 0.150 |
Why?
| | Heart Transplantation | 2 | 2007 | 695 | 0.150 |
Why?
| | Microbial Sensitivity Tests | 8 | 2005 | 347 | 0.150 |
Why?
| | Cholera Toxin | 1 | 2018 | 31 | 0.150 |
Why?
| | Autophagosomes | 1 | 2018 | 20 | 0.150 |
Why?
| | Infant, Premature, Diseases | 3 | 1995 | 104 | 0.150 |
Why?
| | Liver Transplantation | 1 | 2006 | 843 | 0.140 |
Why?
| | Age Distribution | 3 | 2016 | 397 | 0.140 |
Why?
| | Sex Distribution | 3 | 2016 | 380 | 0.140 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2018 | 71 | 0.140 |
Why?
| | Viral Fusion Proteins | 1 | 2017 | 19 | 0.140 |
Why?
| | Lymphocytes | 8 | 1998 | 399 | 0.140 |
Why?
| | Immune Evasion | 1 | 2018 | 58 | 0.140 |
Why?
| | Drug Therapy, Combination | 4 | 2016 | 1043 | 0.140 |
Why?
| | Simian virus 40 | 11 | 1977 | 25 | 0.140 |
Why?
| | Regression Analysis | 2 | 2019 | 1014 | 0.140 |
Why?
| | Genes, Viral | 2 | 2006 | 92 | 0.140 |
Why?
| | Lysosomes | 1 | 2018 | 145 | 0.140 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2017 | 71 | 0.140 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2017 | 50 | 0.140 |
Why?
| | Multivariate Analysis | 2 | 2018 | 1495 | 0.140 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2017 | 6 | 0.140 |
Why?
| | Protein Subunits | 1 | 2018 | 242 | 0.140 |
Why?
| | Disease Transmission, Infectious | 1 | 2018 | 67 | 0.140 |
Why?
| | Cryopreservation | 1 | 2018 | 104 | 0.140 |
Why?
| | Cell Division | 5 | 2003 | 790 | 0.130 |
Why?
| | Models, Biological | 1 | 2005 | 1785 | 0.130 |
Why?
| | Cost of Illness | 5 | 2014 | 309 | 0.130 |
Why?
| | Observational Studies as Topic | 1 | 2017 | 118 | 0.130 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2017 | 77 | 0.130 |
Why?
| | Infectious Mononucleosis | 2 | 1991 | 10 | 0.130 |
Why?
| | Receptors, Muscarinic | 1 | 1996 | 21 | 0.130 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 1996 | 33 | 0.130 |
Why?
| | Infusions, Intravenous | 2 | 2016 | 400 | 0.130 |
Why?
| | Antibodies, Bacterial | 3 | 2013 | 146 | 0.130 |
Why?
| | Africa | 1 | 2017 | 117 | 0.130 |
Why?
| | Depression | 3 | 2013 | 1464 | 0.130 |
Why?
| | Foscarnet | 3 | 2003 | 19 | 0.130 |
Why?
| | Triatoma | 2 | 2006 | 7 | 0.130 |
Why?
| | Nelfinavir | 1 | 2016 | 9 | 0.130 |
Why?
| | Latex Fixation Tests | 1 | 1996 | 4 | 0.120 |
Why?
| | Erythema | 1 | 2016 | 29 | 0.120 |
Why?
| | Comorbidity | 3 | 2019 | 1645 | 0.120 |
Why?
| | Frailty | 1 | 2019 | 172 | 0.120 |
Why?
| | Lopinavir | 1 | 2016 | 30 | 0.120 |
Why?
| | Insect Vectors | 2 | 2006 | 38 | 0.120 |
Why?
| | Atazanavir Sulfate | 1 | 2016 | 44 | 0.120 |
Why?
| | Peptide Fragments | 3 | 2007 | 691 | 0.120 |
Why?
| | HIV Protease Inhibitors | 1 | 2016 | 68 | 0.120 |
Why?
| | Ribavirin | 2 | 1994 | 95 | 0.120 |
Why?
| | Autophagy | 1 | 2018 | 286 | 0.120 |
Why?
| | Ritonavir | 1 | 2016 | 75 | 0.120 |
Why?
| | Hospitalization | 2 | 2023 | 2203 | 0.120 |
Why?
| | Bone Marrow Transplantation | 3 | 1990 | 290 | 0.120 |
Why?
| | Dipeptides | 1 | 2015 | 51 | 0.120 |
Why?
| | Lymphocyte Subsets | 1 | 2015 | 88 | 0.120 |
Why?
| | BK Virus | 1 | 2015 | 17 | 0.120 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2018 | 417 | 0.120 |
Why?
| | Brain Stem | 1 | 1995 | 96 | 0.120 |
Why?
| | Genotype | 3 | 2008 | 1873 | 0.110 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 254 | 0.110 |
Why?
| | Chronic Disease | 6 | 2019 | 1798 | 0.110 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2015 | 658 | 0.110 |
Why?
| | Host-Pathogen Interactions | 1 | 2018 | 375 | 0.110 |
Why?
| | Guatemala | 1 | 2016 | 327 | 0.110 |
Why?
| | Data Interpretation, Statistical | 3 | 2019 | 362 | 0.110 |
Why?
| | Propylene Glycols | 1 | 2015 | 27 | 0.110 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1437 | 0.110 |
Why?
| | Medication Reconciliation | 1 | 2015 | 30 | 0.110 |
Why?
| | Global Health | 1 | 2018 | 382 | 0.110 |
Why?
| | Reproducibility of Results | 5 | 2013 | 3300 | 0.110 |
Why?
| | Survival Rate | 3 | 2016 | 1934 | 0.110 |
Why?
| | Sphingosine | 1 | 2015 | 45 | 0.110 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 114 | 0.110 |
Why?
| | Transfusion Reaction | 1 | 1995 | 61 | 0.110 |
Why?
| | COS Cells | 2 | 2007 | 183 | 0.110 |
Why?
| | Maus Elberfeld virus | 2 | 1991 | 5 | 0.110 |
Why?
| | Respiratory Syncytial Viruses | 4 | 1993 | 54 | 0.110 |
Why?
| | Immunity, Mucosal | 2 | 2012 | 96 | 0.110 |
Why?
| | Maternal-Fetal Exchange | 3 | 1995 | 165 | 0.110 |
Why?
| | Chlamydia trachomatis | 2 | 1991 | 50 | 0.110 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2021 | 97 | 0.110 |
Why?
| | Species Specificity | 3 | 2006 | 581 | 0.110 |
Why?
| | Histocompatibility Antigens Class I | 1 | 1996 | 203 | 0.110 |
Why?
| | Hemagglutinins, Viral | 1 | 1994 | 7 | 0.110 |
Why?
| | Laryngeal Diseases | 1 | 1994 | 30 | 0.110 |
Why?
| | DNA-Directed DNA Polymerase | 2 | 1992 | 45 | 0.110 |
Why?
| | Rats | 4 | 2006 | 5565 | 0.110 |
Why?
| | Needs Assessment | 1 | 2016 | 379 | 0.100 |
Why?
| | Lymphoma | 1 | 2015 | 229 | 0.100 |
Why?
| | Autoantigens | 1 | 1996 | 423 | 0.100 |
Why?
| | Immunoglobulins, Intravenous | 5 | 1995 | 130 | 0.100 |
Why?
| | Zidovudine | 2 | 2015 | 79 | 0.100 |
Why?
| | Lamivudine | 2 | 2015 | 65 | 0.100 |
Why?
| | Analgesics | 3 | 2010 | 210 | 0.100 |
Why?
| | Cross-Over Studies | 2 | 2013 | 550 | 0.100 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2013 | 28 | 0.100 |
Why?
| | Placenta | 2 | 1991 | 752 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 3 | 2013 | 474 | 0.100 |
Why?
| | Ethics, Research | 1 | 2013 | 35 | 0.100 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1545 | 0.100 |
Why?
| | Research Subjects | 1 | 2013 | 43 | 0.100 |
Why?
| | Health Status | 2 | 2010 | 820 | 0.100 |
Why?
| | Mice, Inbred BALB C | 3 | 2006 | 1260 | 0.100 |
Why?
| | RNA Probes | 2 | 1991 | 13 | 0.100 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2014 | 184 | 0.100 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1996 | 290 | 0.100 |
Why?
| | Risk Assessment | 4 | 2016 | 3452 | 0.100 |
Why?
| | Autoimmune Diseases | 1 | 1996 | 454 | 0.100 |
Why?
| | Measles Vaccine | 1 | 2012 | 20 | 0.100 |
Why?
| | Picornaviridae Infections | 2 | 1990 | 50 | 0.100 |
Why?
| | Killer Cells, Natural | 1 | 1996 | 455 | 0.090 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2012 | 99 | 0.090 |
Why?
| | Indoles | 1 | 2015 | 411 | 0.090 |
Why?
| | Drug Resistance, Microbial | 4 | 2001 | 64 | 0.090 |
Why?
| | Human papillomavirus 31 | 1 | 2011 | 1 | 0.090 |
Why?
| | Ureaplasma urealyticum | 1 | 1991 | 3 | 0.090 |
Why?
| | Colorado | 4 | 2018 | 4526 | 0.090 |
Why?
| | Immunosuppressive Agents | 3 | 2015 | 864 | 0.090 |
Why?
| | Meningitis, Aseptic | 1 | 1991 | 13 | 0.090 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2011 | 174 | 0.090 |
Why?
| | Flow Cytometry | 5 | 2017 | 1197 | 0.090 |
Why?
| | Insurance, Health | 1 | 2014 | 292 | 0.090 |
Why?
| | Efficiency | 1 | 2012 | 99 | 0.090 |
Why?
| | Chorioamnionitis | 1 | 1991 | 42 | 0.090 |
Why?
| | Linear Models | 2 | 2010 | 851 | 0.090 |
Why?
| | Mutation | 5 | 2009 | 3993 | 0.090 |
Why?
| | Macrophages | 3 | 2005 | 1544 | 0.090 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 1996 | 39 | 0.090 |
Why?
| | Gastroenteritis | 2 | 1989 | 68 | 0.090 |
Why?
| | Neurogenesis | 1 | 2012 | 150 | 0.090 |
Why?
| | Neural Stem Cells | 1 | 2012 | 156 | 0.090 |
Why?
| | Drug Design | 1 | 2012 | 165 | 0.090 |
Why?
| | Sequence Alignment | 2 | 2008 | 360 | 0.090 |
Why?
| | Adjuvants, Pharmaceutic | 2 | 2022 | 12 | 0.080 |
Why?
| | Epidemiological Monitoring | 3 | 2018 | 65 | 0.080 |
Why?
| | Cervix Uteri | 1 | 2010 | 52 | 0.080 |
Why?
| | Exanthema | 1 | 2011 | 80 | 0.080 |
Why?
| | Serum | 1 | 2010 | 60 | 0.080 |
Why?
| | Sensitivity and Specificity | 3 | 2009 | 1951 | 0.080 |
Why?
| | Electrocardiography | 2 | 2005 | 610 | 0.080 |
Why?
| | Adenoviridae | 9 | 2005 | 200 | 0.080 |
Why?
| | Herpesviridae | 2 | 1981 | 23 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2018 | 999 | 0.080 |
Why?
| | Heart Rate | 2 | 2006 | 793 | 0.080 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2010 | 31 | 0.080 |
Why?
| | Herpesvirus Vaccines | 1 | 2010 | 4 | 0.080 |
Why?
| | Antigen-Presenting Cells | 5 | 2010 | 157 | 0.080 |
Why?
| | Immunoglobulin M | 1 | 1991 | 290 | 0.080 |
Why?
| | Enterovirus B, Human | 2 | 1988 | 26 | 0.080 |
Why?
| | Respiratory Tract Infections | 1 | 1994 | 384 | 0.080 |
Why?
| | Dermatomyositis | 1 | 1989 | 22 | 0.080 |
Why?
| | DNA, Kinetoplast | 2 | 2006 | 2 | 0.080 |
Why?
| | Medicaid | 1 | 2014 | 442 | 0.080 |
Why?
| | Pilot Projects | 1 | 2015 | 1743 | 0.080 |
Why?
| | Poliovirus | 2 | 2001 | 85 | 0.080 |
Why?
| | Hepatitis B Vaccines | 1 | 2009 | 44 | 0.080 |
Why?
| | Receptors, Virus | 2 | 2006 | 94 | 0.080 |
Why?
| | Placenta Diseases | 1 | 1989 | 17 | 0.080 |
Why?
| | Surveys and Questionnaires | 7 | 2021 | 5860 | 0.080 |
Why?
| | Protozoan Infections | 1 | 1989 | 11 | 0.080 |
Why?
| | Drug Stability | 1 | 2009 | 161 | 0.080 |
Why?
| | DNA Primers | 2 | 2009 | 508 | 0.080 |
Why?
| | Thymidine Kinase | 4 | 2001 | 15 | 0.080 |
Why?
| | Skin Diseases, Viral | 1 | 2008 | 6 | 0.080 |
Why?
| | Oligonucleotide Probes | 1 | 1988 | 51 | 0.080 |
Why?
| | Postoperative Complications | 2 | 2000 | 2678 | 0.070 |
Why?
| | Geriatrics | 1 | 2010 | 98 | 0.070 |
Why?
| | Vagina | 1 | 2010 | 187 | 0.070 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 1986 | 72 | 0.070 |
Why?
| | Gene Expression | 2 | 2006 | 1491 | 0.070 |
Why?
| | Geriatric Assessment | 1 | 2010 | 221 | 0.070 |
Why?
| | Muscles | 1 | 1989 | 331 | 0.070 |
Why?
| | Interferon Type I | 1 | 1989 | 141 | 0.070 |
Why?
| | Administration, Intranasal | 1 | 2008 | 89 | 0.070 |
Why?
| | Kinetics | 2 | 2010 | 1641 | 0.070 |
Why?
| | Hydrocortisone | 1 | 2010 | 313 | 0.070 |
Why?
| | Poisson Distribution | 2 | 2005 | 75 | 0.070 |
Why?
| | In Vitro Techniques | 6 | 2003 | 1089 | 0.070 |
Why?
| | Anticonvulsants | 1 | 2010 | 215 | 0.070 |
Why?
| | Lipid A | 2 | 2018 | 28 | 0.070 |
Why?
| | Picornaviridae | 1 | 1988 | 20 | 0.070 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1988 | 28 | 0.070 |
Why?
| | Pertussis Vaccine | 1 | 2007 | 24 | 0.070 |
Why?
| | Evidence-Based Practice | 1 | 2010 | 233 | 0.070 |
Why?
| | Immunosorbent Techniques | 1 | 2007 | 20 | 0.070 |
Why?
| | Quality-Adjusted Life Years | 1 | 2007 | 109 | 0.070 |
Why?
| | Spinal Cord | 2 | 2001 | 373 | 0.070 |
Why?
| | Prevalence | 4 | 2018 | 2744 | 0.070 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 806 | 0.070 |
Why?
| | Pregnancy Outcome | 1 | 2010 | 423 | 0.070 |
Why?
| | Data Collection | 1 | 2010 | 661 | 0.070 |
Why?
| | Cricetulus | 1 | 2007 | 110 | 0.070 |
Why?
| | Receptor, IGF Type 2 | 1 | 2006 | 6 | 0.070 |
Why?
| | Veterans | 1 | 2018 | 1477 | 0.070 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 88 | 0.060 |
Why?
| | Vero Cells | 1 | 2006 | 87 | 0.060 |
Why?
| | Trypanosomatina | 1 | 2006 | 1 | 0.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1996 | 1755 | 0.060 |
Why?
| | Opportunistic Infections | 3 | 1993 | 46 | 0.060 |
Why?
| | Heparitin Sulfate | 1 | 2006 | 46 | 0.060 |
Why?
| | Research | 1 | 2010 | 450 | 0.060 |
Why?
| | Immunoglobulin Fragments | 1 | 2006 | 12 | 0.060 |
Why?
| | Public Health | 1 | 2012 | 582 | 0.060 |
Why?
| | Animal Diseases | 1 | 2006 | 8 | 0.060 |
Why?
| | Neutralization Tests | 5 | 2012 | 81 | 0.060 |
Why?
| | NIH 3T3 Cells | 1 | 2006 | 146 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2021 | 764 | 0.060 |
Why?
| | Administration, Topical | 4 | 2013 | 147 | 0.060 |
Why?
| | Cyclic AMP | 1 | 2007 | 219 | 0.060 |
Why?
| | Immunoglobulin Variable Region | 1 | 2006 | 79 | 0.060 |
Why?
| | Random Allocation | 6 | 1992 | 361 | 0.060 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 902 | 0.060 |
Why?
| | Trees | 1 | 2006 | 69 | 0.060 |
Why?
| | Meningococcal Vaccines | 1 | 2006 | 64 | 0.060 |
Why?
| | Nasopharyngeal Diseases | 1 | 1985 | 5 | 0.060 |
Why?
| | Pneumonia, Viral | 2 | 1990 | 369 | 0.060 |
Why?
| | Hybridization, Genetic | 9 | 1974 | 77 | 0.060 |
Why?
| | Logistic Models | 2 | 2010 | 2083 | 0.060 |
Why?
| | Bone Marrow | 2 | 1984 | 300 | 0.060 |
Why?
| | Motor Activity | 1 | 2010 | 711 | 0.060 |
Why?
| | Endocytosis | 1 | 2006 | 175 | 0.060 |
Why?
| | Sequence Analysis, DNA | 3 | 2007 | 826 | 0.060 |
Why?
| | GB virus C | 1 | 2005 | 1 | 0.060 |
Why?
| | Flaviviridae Infections | 1 | 2005 | 2 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2009 | 1284 | 0.060 |
Why?
| | Hepatitis, Viral, Human | 1 | 2005 | 22 | 0.060 |
Why?
| | Predictive Value of Tests | 3 | 2010 | 2037 | 0.060 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 2158 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 556 | 0.060 |
Why?
| | Normal Distribution | 1 | 2005 | 21 | 0.060 |
Why?
| | Uterine Cervical Dysplasia | 2 | 2016 | 44 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2012 | 1999 | 0.060 |
Why?
| | HLA Antigens | 3 | 1987 | 240 | 0.060 |
Why?
| | Evaluation Studies as Topic | 3 | 1996 | 174 | 0.060 |
Why?
| | Conservation of Natural Resources | 1 | 2006 | 126 | 0.060 |
Why?
| | Transfection | 1 | 2007 | 941 | 0.060 |
Why?
| | Organ Transplantation | 1 | 2008 | 250 | 0.060 |
Why?
| | Autopsy | 2 | 2001 | 94 | 0.060 |
Why?
| | Open Reading Frames | 2 | 2007 | 132 | 0.060 |
Why?
| | Blotting, Western | 3 | 2015 | 1224 | 0.060 |
Why?
| | Neurons, Afferent | 1 | 2005 | 97 | 0.060 |
Why?
| | Mammals | 1 | 2006 | 286 | 0.060 |
Why?
| | Receptors, Cholinergic | 1 | 2004 | 40 | 0.050 |
Why?
| | Risk | 3 | 2016 | 908 | 0.050 |
Why?
| | Disease Outbreaks | 1 | 1988 | 417 | 0.050 |
Why?
| | Macaca radiata | 2 | 2001 | 16 | 0.050 |
Why?
| | Cell Culture Techniques | 1 | 2006 | 364 | 0.050 |
Why?
| | Cell Adhesion Molecules | 1 | 2005 | 176 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2015 | 2027 | 0.050 |
Why?
| | Mental Health | 1 | 2010 | 735 | 0.050 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2004 | 69 | 0.050 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2003 | 66 | 0.050 |
Why?
| | Sex Factors | 2 | 2003 | 2055 | 0.050 |
Why?
| | Abdominal Neoplasms | 1 | 2003 | 39 | 0.050 |
Why?
| | Demography | 2 | 2018 | 296 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2005 | 392 | 0.050 |
Why?
| | Multicenter Studies as Topic | 2 | 2001 | 307 | 0.050 |
Why?
| | 2-Aminopurine | 2 | 2007 | 8 | 0.050 |
Why?
| | RNA | 2 | 1988 | 927 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2009 | 2143 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2005 | 500 | 0.050 |
Why?
| | Adaptive Immunity | 2 | 2017 | 172 | 0.050 |
Why?
| | Biopsy | 2 | 2000 | 1093 | 0.050 |
Why?
| | Argentina | 3 | 2006 | 27 | 0.050 |
Why?
| | Neuroblastoma | 1 | 2003 | 160 | 0.050 |
Why?
| | Poliomyelitis | 2 | 2001 | 37 | 0.050 |
Why?
| | Forecasting | 3 | 2010 | 384 | 0.050 |
Why?
| | Maltose-Binding Proteins | 1 | 2001 | 13 | 0.050 |
Why?
| | Glutathione Transferase | 1 | 2001 | 102 | 0.050 |
Why?
| | Cell Nucleus | 3 | 1991 | 611 | 0.040 |
Why?
| | Hepatitis C | 1 | 2004 | 274 | 0.040 |
Why?
| | Respirovirus Infections | 2 | 1991 | 13 | 0.040 |
Why?
| | Spondylarthropathies | 1 | 2021 | 6 | 0.040 |
Why?
| | Poliovirus Vaccine, Oral | 1 | 2001 | 25 | 0.040 |
Why?
| | Interspersed Repetitive Sequences | 1 | 2000 | 5 | 0.040 |
Why?
| | Alanine | 1 | 2001 | 152 | 0.040 |
Why?
| | Peripheral Nerves | 1 | 2001 | 67 | 0.040 |
Why?
| | Blotting, Southern | 1 | 2000 | 75 | 0.040 |
Why?
| | Mutagenesis | 1 | 2001 | 183 | 0.040 |
Why?
| | Expressed Sequence Tags | 1 | 2000 | 42 | 0.040 |
Why?
| | Secondary Prevention | 2 | 2013 | 235 | 0.040 |
Why?
| | Endocardium | 1 | 2000 | 30 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2001 | 311 | 0.040 |
Why?
| | Cloning, Molecular | 1 | 2001 | 535 | 0.040 |
Why?
| | Blotting, Northern | 1 | 2000 | 201 | 0.040 |
Why?
| | Sex Characteristics | 2 | 2017 | 767 | 0.040 |
Why?
| | Phosphorylation | 2 | 2002 | 1761 | 0.040 |
Why?
| | Genome, Viral | 1 | 2002 | 222 | 0.040 |
Why?
| | Virion | 1 | 2001 | 113 | 0.040 |
Why?
| | DNA, Protozoan | 1 | 2000 | 32 | 0.040 |
Why?
| | Consensus Sequence | 1 | 2000 | 72 | 0.040 |
Why?
| | Amino Acid Motifs | 1 | 2000 | 224 | 0.040 |
Why?
| | DEAD-box RNA Helicases | 1 | 2000 | 75 | 0.040 |
Why?
| | Psoriasis | 1 | 2021 | 109 | 0.040 |
Why?
| | Canada | 2 | 2012 | 409 | 0.040 |
Why?
| | Sleep | 1 | 2006 | 794 | 0.040 |
Why?
| | Amniotic Fluid | 3 | 1991 | 81 | 0.040 |
Why?
| | Autoimmunity | 1 | 2005 | 901 | 0.040 |
Why?
| | Transcription, Genetic | 5 | 2000 | 1458 | 0.040 |
Why?
| | Chromosome Mapping | 1 | 2000 | 515 | 0.040 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2000 | 392 | 0.040 |
Why?
| | Enterotoxins | 2 | 1994 | 88 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2001 | 662 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2472 | 0.040 |
Why?
| | Saponins | 1 | 2018 | 9 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 1 | 1982 | 410 | 0.040 |
Why?
| | Saliva | 2 | 2010 | 239 | 0.040 |
Why?
| | Haptoglobins | 1 | 2018 | 54 | 0.040 |
Why?
| | Seroconversion | 1 | 2018 | 45 | 0.040 |
Why?
| | Drug Compounding | 1 | 2018 | 101 | 0.040 |
Why?
| | Encephalitis, Viral | 1 | 1998 | 45 | 0.040 |
Why?
| | Protein Precursors | 1 | 2018 | 133 | 0.030 |
Why?
| | Celiac Disease | 1 | 2021 | 290 | 0.030 |
Why?
| | Immunologic Techniques | 2 | 1994 | 40 | 0.030 |
Why?
| | Glucosides | 1 | 2017 | 47 | 0.030 |
Why?
| | Inositol Phosphates | 1 | 2017 | 23 | 0.030 |
Why?
| | Sterols | 1 | 2017 | 20 | 0.030 |
Why?
| | Botswana | 1 | 2017 | 9 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 5 | 1977 | 333 | 0.030 |
Why?
| | International Cooperation | 1 | 2018 | 204 | 0.030 |
Why?
| | Health Surveys | 1 | 2019 | 521 | 0.030 |
Why?
| | Internationality | 1 | 2018 | 158 | 0.030 |
Why?
| | Zimbabwe | 1 | 2017 | 59 | 0.030 |
Why?
| | Chemotaxis | 1 | 2017 | 133 | 0.030 |
Why?
| | Zambia | 1 | 2017 | 57 | 0.030 |
Why?
| | Tanzania | 1 | 2017 | 57 | 0.030 |
Why?
| | Antigens, Bacterial | 1 | 2017 | 125 | 0.030 |
Why?
| | Bisoprolol | 1 | 1996 | 2 | 0.030 |
Why?
| | Plasma | 1 | 2018 | 217 | 0.030 |
Why?
| | Patient Safety | 1 | 2020 | 320 | 0.030 |
Why?
| | Recovery of Function | 1 | 2021 | 666 | 0.030 |
Why?
| | Graft Rejection | 1 | 2000 | 577 | 0.030 |
Why?
| | Propanolamines | 1 | 1996 | 38 | 0.030 |
Why?
| | Cerebrospinal Fluid | 2 | 1993 | 90 | 0.030 |
Why?
| | Biomarkers | 2 | 2018 | 4101 | 0.030 |
Why?
| | Immune Tolerance | 4 | 1998 | 366 | 0.030 |
Why?
| | Acute Disease | 2 | 2011 | 1006 | 0.030 |
Why?
| | Leukemia, Lymphoid | 2 | 1986 | 27 | 0.030 |
Why?
| | Sinusitis | 1 | 1999 | 231 | 0.030 |
Why?
| | False Negative Reactions | 1 | 1996 | 56 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2016 | 84 | 0.030 |
Why?
| | False Positive Reactions | 1 | 1996 | 125 | 0.030 |
Why?
| | Amniocentesis | 2 | 1991 | 20 | 0.030 |
Why?
| | Cross-Sectional Studies | 4 | 2011 | 5518 | 0.030 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2015 | 49 | 0.030 |
Why?
| | AIDS Dementia Complex | 1 | 2015 | 51 | 0.030 |
Why?
| | Half-Life | 2 | 1992 | 145 | 0.030 |
Why?
| | Nevirapine | 1 | 2015 | 17 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1314 | 0.030 |
Why?
| | Depressive Disorder | 1 | 1998 | 389 | 0.030 |
Why?
| | Adrenergic beta-Antagonists | 1 | 1996 | 227 | 0.030 |
Why?
| | Nausea | 1 | 2015 | 111 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 524 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 308 | 0.030 |
Why?
| | Vomiting | 1 | 2015 | 131 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 310 | 0.030 |
Why?
| | Bromodeoxyuridine | 2 | 2007 | 79 | 0.030 |
Why?
| | Fingolimod Hydrochloride | 1 | 2015 | 40 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2015 | 60 | 0.030 |
Why?
| | Breast Feeding | 1 | 2018 | 434 | 0.030 |
Why?
| | Headache | 1 | 2015 | 147 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 1996 | 349 | 0.030 |
Why?
| | Neutropenia | 1 | 2015 | 158 | 0.030 |
Why?
| | Belgium | 1 | 2014 | 11 | 0.030 |
Why?
| | Vaccines, Virus-Like Particle | 1 | 2014 | 3 | 0.030 |
Why?
| | Bacterial Proteins | 1 | 2000 | 897 | 0.030 |
Why?
| | Metabolic Diseases | 1 | 2015 | 109 | 0.030 |
Why?
| | HLA-A2 Antigen | 1 | 2014 | 49 | 0.030 |
Why?
| | Rubella | 1 | 1974 | 23 | 0.030 |
Why?
| | Culture Media | 2 | 1984 | 163 | 0.030 |
Why?
| | Probability | 2 | 2005 | 308 | 0.030 |
Why?
| | Tetanus Toxoid | 1 | 1994 | 37 | 0.030 |
Why?
| | Immunoblotting | 1 | 1994 | 306 | 0.030 |
Why?
| | Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1994 | 25 | 0.030 |
Why?
| | Drugs, Investigational | 1 | 2014 | 32 | 0.030 |
Why?
| | Anemia | 1 | 2015 | 174 | 0.030 |
Why?
| | Seroepidemiologic Studies | 1 | 2014 | 164 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2004 | 430 | 0.030 |
Why?
| | Phenotype | 1 | 2002 | 3153 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2015 | 201 | 0.030 |
Why?
| | Developed Countries | 1 | 2013 | 39 | 0.020 |
Why?
| | Mortality | 1 | 2015 | 355 | 0.020 |
Why?
| | Haplorhini | 8 | 1974 | 52 | 0.020 |
Why?
| | Human papillomavirus 6 | 1 | 2011 | 4 | 0.020 |
Why?
| | Drug Tolerance | 1 | 1992 | 104 | 0.020 |
Why?
| | Ureaplasma Infections | 1 | 1991 | 3 | 0.020 |
Why?
| | Skin | 2 | 1989 | 752 | 0.020 |
Why?
| | Arthritis, Rheumatoid | 1 | 2021 | 1156 | 0.020 |
Why?
| | Mycoplasma Infections | 1 | 1991 | 16 | 0.020 |
Why?
| | Safety | 1 | 1994 | 345 | 0.020 |
Why?
| | Genetics, Microbial | 3 | 1971 | 10 | 0.020 |
Why?
| | Genitalia, Female | 1 | 2012 | 39 | 0.020 |
Why?
| | gamma-Globulins | 1 | 1991 | 18 | 0.020 |
Why?
| | Antibodies, Heterophile | 1 | 1991 | 13 | 0.020 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 1991 | 12 | 0.020 |
Why?
| | Metabolomics | 1 | 2017 | 686 | 0.020 |
Why?
| | Phylogeny | 2 | 2006 | 1006 | 0.020 |
Why?
| | Consensus | 1 | 2015 | 674 | 0.020 |
Why?
| | Absenteeism | 1 | 2012 | 52 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2015 | 493 | 0.020 |
Why?
| | Adenoviruses, Human | 1 | 1991 | 27 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2016 | 432 | 0.020 |
Why?
| | Hospitals, University | 1 | 1991 | 179 | 0.020 |
Why?
| | Inflammation | 2 | 2017 | 2843 | 0.020 |
Why?
| | Matched-Pair Analysis | 1 | 2011 | 38 | 0.020 |
Why?
| | Bodily Secretions | 1 | 2010 | 2 | 0.020 |
Why?
| | North America | 1 | 2012 | 310 | 0.020 |
Why?
| | Paramyxoviridae Infections | 1 | 1990 | 13 | 0.020 |
Why?
| | Diagnosis, Differential | 3 | 2009 | 1492 | 0.020 |
Why?
| | Tritium | 7 | 1974 | 72 | 0.020 |
Why?
| | Europe | 1 | 2012 | 406 | 0.020 |
Why?
| | Chlamydia Infections | 1 | 1991 | 78 | 0.020 |
Why?
| | Schwann Cells | 1 | 1990 | 34 | 0.020 |
Why?
| | Antigens | 2 | 1970 | 356 | 0.020 |
Why?
| | DNA | 4 | 1988 | 1448 | 0.020 |
Why?
| | Bacterial Infections | 2 | 2001 | 245 | 0.020 |
Why?
| | Rhinovirus | 1 | 1990 | 57 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2470 | 0.020 |
Why?
| | Antigens, Surface | 2 | 1987 | 153 | 0.020 |
Why?
| | Serotyping | 2 | 1988 | 33 | 0.020 |
Why?
| | Health Planning Guidelines | 1 | 2010 | 24 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2015 | 801 | 0.020 |
Why?
| | Self Administration | 1 | 2010 | 126 | 0.020 |
Why?
| | Gestational Age | 2 | 1989 | 916 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1754 | 0.020 |
Why?
| | Hepatitis B Antibodies | 1 | 2009 | 11 | 0.020 |
Why?
| | beta-Globins | 1 | 2009 | 8 | 0.020 |
Why?
| | Contraceptive Devices, Male | 1 | 1989 | 1 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 610 | 0.020 |
Why?
| | In Situ Hybridization | 2 | 2001 | 320 | 0.020 |
Why?
| | Subacute Sclerosing Panencephalitis | 1 | 1989 | 6 | 0.020 |
Why?
| | Spermatocidal Agents | 1 | 1989 | 7 | 0.020 |
Why?
| | Ribonucleosides | 1 | 1989 | 6 | 0.020 |
Why?
| | Reference Values | 1 | 2011 | 801 | 0.020 |
Why?
| | Physical Examination | 1 | 2010 | 242 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1993 | 1727 | 0.020 |
Why?
| | Thymidine | 4 | 1980 | 60 | 0.020 |
Why?
| | RNA, Antisense | 1 | 1988 | 17 | 0.020 |
Why?
| | Nasal Mucosa | 1 | 2009 | 106 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 184 | 0.020 |
Why?
| | Astrocytes | 1 | 1990 | 211 | 0.020 |
Why?
| | Virus Cultivation | 4 | 1984 | 31 | 0.020 |
Why?
| | Measles | 1 | 1989 | 45 | 0.020 |
Why?
| | Reoviridae | 1 | 1988 | 37 | 0.020 |
Why?
| | Mammalian orthoreovirus 3 | 1 | 1988 | 37 | 0.020 |
Why?
| | Hepatitis | 1 | 1988 | 47 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2734 | 0.020 |
Why?
| | DNA, Recombinant | 1 | 1988 | 48 | 0.020 |
Why?
| | Reoviridae Infections | 1 | 1988 | 55 | 0.020 |
Why?
| | Cancer Vaccines | 1 | 2009 | 166 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 1969 | 174 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2010 | 279 | 0.020 |
Why?
| | Fetus | 1 | 1992 | 801 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1988 | 158 | 0.020 |
Why?
| | Cytopathogenic Effect, Viral | 2 | 1982 | 16 | 0.020 |
Why?
| | Microscopy, Electron | 3 | 2001 | 435 | 0.020 |
Why?
| | Body Fluids | 1 | 1987 | 70 | 0.020 |
Why?
| | Telomere | 1 | 2010 | 276 | 0.020 |
Why?
| | Noma | 1 | 1986 | 2 | 0.020 |
Why?
| | Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2006 | 13 | 0.020 |
Why?
| | Biliary Atresia | 1 | 1988 | 154 | 0.020 |
Why?
| | Australia | 1 | 2008 | 302 | 0.020 |
Why?
| | Xenodiagnosis | 1 | 2006 | 2 | 0.020 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 1988 | 134 | 0.020 |
Why?
| | Valine | 1 | 2007 | 79 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2556 | 0.020 |
Why?
| | Anti-Bacterial Agents | 2 | 1999 | 1808 | 0.020 |
Why?
| | Embryo, Mammalian | 3 | 1973 | 235 | 0.020 |
Why?
| | Interleukin-4 | 2 | 1998 | 214 | 0.020 |
Why?
| | Kidney | 9 | 1975 | 1471 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2007 | 309 | 0.020 |
Why?
| | Ketones | 1 | 1986 | 47 | 0.010 |
Why?
| | RNA, Ribosomal | 1 | 2006 | 168 | 0.010 |
Why?
| | Reagent Kits, Diagnostic | 1 | 1985 | 35 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2006 | 295 | 0.010 |
Why?
| | Gene Amplification | 1 | 2006 | 103 | 0.010 |
Why?
| | Nectins | 1 | 2005 | 6 | 0.010 |
Why?
| | Mass Screening | 1 | 2014 | 1287 | 0.010 |
Why?
| | Residence Characteristics | 1 | 2008 | 366 | 0.010 |
Why?
| | Lymphoproliferative Disorders | 1 | 1985 | 59 | 0.010 |
Why?
| | California | 1 | 2006 | 441 | 0.010 |
Why?
| | Factor Analysis, Statistical | 1 | 2006 | 292 | 0.010 |
Why?
| | Toll-Like Receptor 2 | 1 | 2005 | 116 | 0.010 |
Why?
| | Carbon Isotopes | 5 | 1973 | 139 | 0.010 |
Why?
| | Streptococcus pneumoniae | 1 | 2006 | 168 | 0.010 |
Why?
| | Chromosomes, Human | 1 | 1984 | 45 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1985 | 225 | 0.010 |
Why?
| | Toll-Like Receptors | 1 | 2005 | 188 | 0.010 |
Why?
| | Hexuronic Acids | 1 | 1984 | 23 | 0.010 |
Why?
| | Intensive Care Units, Neonatal | 1 | 1988 | 259 | 0.010 |
Why?
| | Glucuronic Acid | 1 | 1984 | 25 | 0.010 |
Why?
| | Alginates | 1 | 1984 | 46 | 0.010 |
Why?
| | Freezing | 1 | 1984 | 88 | 0.010 |
Why?
| | Filtration | 1 | 1984 | 70 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 1989 | 634 | 0.010 |
Why?
| | Culture Techniques | 4 | 1973 | 73 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 1984 | 322 | 0.010 |
Why?
| | RNA, Small Interfering | 1 | 2005 | 621 | 0.010 |
Why?
| | Fetal Blood | 1 | 1985 | 333 | 0.010 |
Why?
| | Stomatitis, Herpetic | 1 | 1982 | 5 | 0.010 |
Why?
| | Phosphonoacetic Acid | 1 | 1982 | 10 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2007 | 1308 | 0.010 |
Why?
| | Up-Regulation | 1 | 2005 | 846 | 0.010 |
Why?
| | Agammaglobulinemia | 1 | 1982 | 34 | 0.010 |
Why?
| | Rural Population | 1 | 2006 | 579 | 0.010 |
Why?
| | Prognosis | 1 | 2010 | 4017 | 0.010 |
Why?
| | Isoelectric Focusing | 1 | 2001 | 31 | 0.010 |
Why?
| | NF-kappa B | 1 | 2005 | 679 | 0.010 |
Why?
| | Ulnar Nerve | 1 | 2001 | 16 | 0.010 |
Why?
| | Brain | 1 | 1993 | 2748 | 0.010 |
Why?
| | Temperature | 1 | 1984 | 664 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2005 | 785 | 0.010 |
Why?
| | Administration, Oral | 2 | 1997 | 788 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 339 | 0.010 |
Why?
| | Cell Survival | 1 | 1984 | 1128 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1991 | 4308 | 0.010 |
Why?
| | Phytohemagglutinins | 1 | 1980 | 28 | 0.010 |
Why?
| | Serum Albumin | 1 | 2001 | 151 | 0.010 |
Why?
| | Ribosomes | 1 | 2001 | 188 | 0.010 |
Why?
| | Neuroglia | 1 | 2001 | 171 | 0.010 |
Why?
| | Cell Communication | 1 | 1982 | 315 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2004 | 574 | 0.010 |
Why?
| | Phagocytosis | 1 | 1982 | 387 | 0.010 |
Why?
| | Leukocytes | 1 | 1981 | 308 | 0.010 |
Why?
| | Air Microbiology | 1 | 1980 | 47 | 0.010 |
Why?
| | Nasal Decongestants | 1 | 1999 | 8 | 0.010 |
Why?
| | Immunity, Maternally-Acquired | 1 | 1979 | 19 | 0.010 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 1999 | 38 | 0.010 |
Why?
| | Immunoglobulins | 1 | 1979 | 169 | 0.010 |
Why?
| | Mitogens | 1 | 1978 | 59 | 0.010 |
Why?
| | Lectins | 1 | 1978 | 46 | 0.010 |
Why?
| | Steroids | 1 | 1999 | 159 | 0.010 |
Why?
| | Rabbits | 1 | 1979 | 766 | 0.010 |
Why?
| | Th2 Cells | 1 | 1998 | 178 | 0.010 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 1993 | 387 | 0.010 |
Why?
| | Amanitins | 1 | 1977 | 4 | 0.010 |
Why?
| | Cross Infection | 1 | 1980 | 250 | 0.010 |
Why?
| | Centrifugation, Density Gradient | 3 | 1971 | 40 | 0.010 |
Why?
| | Antigen-Antibody Complex | 1 | 1997 | 87 | 0.010 |
Why?
| | Interleukin-10 | 1 | 1998 | 304 | 0.010 |
Why?
| | Erythrocytes | 1 | 1982 | 710 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1999 | 1238 | 0.010 |
Why?
| | Adenoviridae Infections | 1 | 1975 | 19 | 0.010 |
Why?
| | Patient Selection | 1 | 1999 | 692 | 0.010 |
Why?
| | Indicator Dilution Techniques | 1 | 1994 | 12 | 0.010 |
Why?
| | Uridine | 2 | 1973 | 30 | 0.010 |
Why?
| | Heart Defects, Congenital | 2 | 1993 | 844 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 1999 | 740 | 0.010 |
Why?
| | Centrifugation, Zonal | 2 | 1971 | 2 | 0.010 |
Why?
| | Abortion, Therapeutic | 1 | 1974 | 3 | 0.010 |
Why?
| | Rubella virus | 1 | 1974 | 9 | 0.010 |
Why?
| | Cesium | 2 | 1971 | 20 | 0.010 |
Why?
| | Molecular Biology | 2 | 1971 | 58 | 0.010 |
Why?
| | Sucrose | 2 | 1971 | 110 | 0.010 |
Why?
| | Chlorides | 2 | 1971 | 139 | 0.010 |
Why?
| | Complement Fixation Tests | 2 | 1984 | 6 | 0.010 |
Why?
| | Pulmonary Fibrosis | 1 | 1975 | 398 | 0.010 |
Why?
| | Hemagglutination Tests | 1 | 1991 | 7 | 0.010 |
Why?
| | Genes | 1 | 1971 | 229 | 0.010 |
Why?
| | Stress, Psychological | 1 | 1998 | 1124 | 0.010 |
Why?
| | Population Surveillance | 1 | 1993 | 480 | 0.010 |
Why?
| | Nonoxynol | 1 | 1989 | 4 | 0.000 |
Why?
| | Latex | 1 | 1989 | 9 | 0.000 |
Why?
| | Kidney Transplantation | 1 | 1975 | 701 | 0.000 |
Why?
| | Suspensions | 1 | 1987 | 27 | 0.000 |
Why?
| | Ribonucleases | 1 | 1987 | 47 | 0.000 |
Why?
| | Chloroquine | 1 | 1987 | 52 | 0.000 |
Why?
| | Deltaretrovirus | 1 | 1986 | 12 | 0.000 |
Why?
| | Binding, Competitive | 1 | 1985 | 195 | 0.000 |
Why?
| | Leukocyte Count | 1 | 1985 | 323 | 0.000 |
Why?
| | Mitosis | 1 | 1985 | 192 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1985 | 365 | 0.000 |
Why?
| | Serologic Tests | 1 | 1983 | 53 | 0.000 |
Why?
| | Histocompatibility Antigens | 2 | 1974 | 106 | 0.000 |
Why?
| | Infusions, Parenteral | 1 | 1982 | 41 | 0.000 |
Why?
| | Leukemia | 1 | 1983 | 241 | 0.000 |
Why?
| | Hospital Bed Capacity, 300 to 499 | 1 | 1980 | 4 | 0.000 |
Why?
| | Air Movements | 1 | 1980 | 10 | 0.000 |
Why?
| | Hospital Units | 1 | 1980 | 29 | 0.000 |
Why?
| | Liver | 1 | 1988 | 1872 | 0.000 |
Why?
| | Boston | 1 | 1980 | 93 | 0.000 |
Why?
| | Communicable Disease Control | 1 | 1980 | 83 | 0.000 |
Why?
| | Methods | 1 | 1978 | 65 | 0.000 |
Why?
| | p-Fluorophenylalanine | 1 | 1976 | 2 | 0.000 |
Why?
| | Cycloheximide | 1 | 1976 | 53 | 0.000 |
Why?
| | Hospitals, Pediatric | 1 | 1980 | 516 | 0.000 |
Why?
| | Inclusion Bodies, Viral | 1 | 1975 | 3 | 0.000 |
Why?
| | Cytoplasm | 1 | 1976 | 269 | 0.000 |
Why?
| | Cadaver | 1 | 1975 | 293 | 0.000 |
Why?
| | Transplantation, Homologous | 1 | 1975 | 414 | 0.000 |
Why?
| | Genetic Code | 1 | 1971 | 22 | 0.000 |
Why?
| | Nucleic Acid Denaturation | 1 | 1971 | 32 | 0.000 |
Why?
| | Chymotrypsin | 1 | 1971 | 23 | 0.000 |
Why?
| | Platinum | 1 | 1971 | 52 | 0.000 |
Why?
| | Molecular Weight | 1 | 1971 | 330 | 0.000 |
Why?
| | DNA Replication | 1 | 1971 | 239 | 0.000 |
Why?
| | Carbon | 1 | 1971 | 203 | 0.000 |
Why?
| | Hot Temperature | 1 | 1971 | 390 | 0.000 |
Why?
| | Lung | 1 | 1975 | 4059 | 0.000 |
Why?
|
|
Levin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|